Genprex, Inc. (GNPX)

USD 0.83

(-18.61%)

Market Cap (In USD)

7.06 Million

Revenue (In USD)

-

Net Income (In USD)

-30.86 Million

Avg. Volume

459.48 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.281-14.4
PE
-
EPS
-
Beta Value
-1.286
ISIN
US3724462037
CUSIP
372446104
CIK
1595248
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Ryan M. Confer M.S.
Employee Count
-
Website
https://www.genprex.com
Ipo Date
2018-03-29
Details
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.